Patents by Inventor Moustafa A. El-Sayed

Moustafa A. El-Sayed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Metabolically stable 5-HMF derivatives for the treatment of hypoxia
    Patent number: 11319292
    Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: May 3, 2022
    Assignees: KING ABDULAZIZ UNIVERSITY, VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA
    Publication number: 20210403434
    Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Application
    Filed: September 7, 2021
    Publication date: December 30, 2021
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA
    Publication number: 20210340109
    Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Application
    Filed: October 7, 2020
    Publication date: November 4, 2021
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • Metabolically stable 5-HMF derivatives for the treatment of hypoxia
    Patent number: 11149012
    Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: October 19, 2021
    Assignees: King Abdulaziz University, Virginia Commonwealth University
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • Metabolically stable vanillin derivatives for the treatment of hypoxia
    Patent number: 11104632
    Abstract: Vanillin derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: August 31, 2021
    Assignee: King Abdulaziz University
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • Metabolically stable 5-HMF derivatives for the treatment of hypoxia
    Patent number: 10836729
    Abstract: 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: November 17, 2020
    Assignee: King Abdulaziz University
    Inventors: Abdelsattar Mansour Ebeid Omar, Moustafa El-Sayed El-Araby, Martin K. Safo
  • Azolylacryloyl derivatives as therapeutic agents for sickle cell disease
    Patent number: 10344001
    Abstract: Azolylacryloyl derivatives with hypoxic properties are provided. The compounds have a generic formula: and are suitable for treating sickle cell disease and hypoxia-underlying diseases, e.g. hemorrhagic and traumatic shock, cardiac arrest and cardiogenic shock, traumatic brain injury, cancer, stroke, myocardial infarction, myocardial ischemia, vaso-occlusive crisis, etc.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 9, 2019
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, KING ABDULAZIZ UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Martin K. Safo, Yan Zhang, Mohini Ghatge, Osheiza Abdulmalik, Abdelsattar Mansour Ebid Omar, Moustafa El-Sayed El-Araby
  • AZOLYLACRYLOYL DERIVATIVES AS THERAPEUTIC AGENTS FOR SICKLE CELL DISEASE
    Publication number: 20180282287
    Abstract: Azolylacryloyl derivatives with hypoxic properties are provided. The compounds have a generic formula: and are suitable for treating sickle cell disease and hypoxia-underlying diseases, e.g. hemorrhagic and traumatic shock, cardiac arrest and cardiogenic shock, traumatic brain injury, cancer, stroke, myocardial infarction, myocardial ischemia, vaso-occlusive crisis, etc.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 4, 2018
    Inventors: Martin K. Safo, Yan Zhang, Mohini Ghatge, Osheiza Abdulmalik, Abdelsattar Mansour Ebid Omar, Moustafa El-Sayed El-Araby
  • Cadmium sulfide quantum dot lasing in room temperature liquid solution
    Publication number: 20090084985
    Abstract: Disclosed is a lasing complex comprising a room temperature solution containing cadmium sulfide (CdS) quantum dots. Optical gain has been observed in CdS nanocrystal quantum dots in strong confinement regime in toluene solution at room temperature using femtosecond transient absorption techniques. The optical gain lifetime is measured to be 20 picoseconds under pump fluence of 0.77 mJ/cm2. The relative lower gain threshold compared to that of CdSe quantum dots is attributed to the long lifetime of fluorescence and biexcitons and the relatively sharp photoluminescence linewidth. The CdS nanocrystals are excellent gain media for semiconductor quantum dot based blue lasers.
    Type: Application
    Filed: June 25, 2008
    Publication date: April 2, 2009
    Inventors: Moustafa A. El-Sayed, Wei Qian, Qusai Darugar